Eli Lilly reported first-quarter earnings and revenue that exceeded Wall Street expectations on Thursday and raised its full-year sales outlook by $2 billion, driven by strong demand for its obesity and diabetes treatments Zepbound and Mounjaro.
30 Apr 2026-15:51
30 Apr 2026-15:51
